Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 338
- Registration Number
- NCT06039189
- Locations
- 🇺🇸
Suzanne Bruce and Associates - The Center for Skin Research, Houston, Texas, United States
🇺🇸Total Dermatology, Birmingham, Alabama, United States
🇺🇸Practice Wang, Riverside, California, United States
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT06028438
- Locations
- 🇵🇱
NZOZ Lecznica MAK MED S C, Nadarzyn, Poland
🇭🇺Vital Medical Center Orvosi es Fogaszati Kozpont, Veszprem, Hungary
🇭🇺Budai Irgalmasrendi Korhaz, Budapest, Hungary
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 320
- Registration Number
- NCT05963074
- Locations
- 🇺🇸
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇮🇹ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
Global Patient Registry of Inherited Retinal Diseases
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7000
- Registration Number
- NCT05957276
- Locations
- 🇦🇺
Centre for Eye Research Australia, East Melbourne, Australia
🇪🇸Hosp. Univ. de Bellvitge, Barcelona, Spain
🇪🇸Hosp. Sant Joan de Deu, Barcelona, Spain
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05923073
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇧🇷Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro, Curitiba, Brazil
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05912517
- Locations
- 🇬🇧
Birmingham Women's Hospital, Birmingham, United Kingdom
🇬🇧St.Mary's Hospital, Manchester, United Kingdom
🇬🇧John Radcliffe Hospital, Oxford, United Kingdom
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT05908734
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇲🇾University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇧🇷Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Brazil
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05896683
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 333
- Registration Number
- NCT05884398
- Locations
- 🇺🇸
Urology Centers Of Alabama, Homewood, Alabama, United States
🇺🇸Arizona Urology Specialists, Tucson, Arizona, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05884242
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium